Illinois General Assembly - Bill Status for HB3583
Illinois General Assembly

  Bills & Resolutions  
  Compiled Statutes  
  Public Acts  
  Legislative Reports  
  IL Constitution  
  Legislative Guide  
  Legislative Glossary  

 Search By Number
 (example: HB0001)
Search Tips

Search By Keyword

 Bill Status of HB3583  102nd General Assembly


Short Description:  AFFORDABLE DRUG MANUFACTURING

House Sponsors
Rep. Dagmara Avelar and Daniel Didech

Last Action
DateChamber Action
  3/27/2021HouseRule 19(a) / Re-referred to Rules Committee

Statutes Amended In Order of Appearance
New Act
5 ILCS 140/7.5


Synopsis As Introduced
Creates the Affordable Drug Manufacturing Act. Provides that the Department of Public Health shall enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. Requires the partnerships to result in the production or distribution of generic prescription drugs with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers, and pharmacies. Provides that the Department shall comply with specified requirements when entering into partnerships or setting prices for generic prescription drugs. Requires the Department to submit separate reports to the General Assembly that (1) assess the feasibility of directly manufacturing generic prescription drugs and selling generic prescription drugs at a fair price; and (2) describe the status of all drugs targeted under the Act and analyze how the activities of the Department may impact competition, access to targeted drugs, the costs of those drugs, and the costs of generic prescription drugs to public and private purchasers. Contains other provisions. Amends the Freedom of Information Act to exempt certain information disclosed under the Affordable Drug Manufacturing Act is exempt from disclosure under the Act. Contains a severability provision. Effective July 1, 2021.

Actions 
DateChamber Action
  2/19/2021HouseFiled with the Clerk by Rep. Dagmara Avelar
  2/22/2021HouseFirst Reading
  2/22/2021HouseReferred to Rules Committee
  3/16/2021HouseAssigned to Prescription Drug Affordability & Accessibility Committee
  3/22/2021HouseHouse Committee Amendment No. 1 Filed with Clerk by Rep. Dagmara Avelar
  3/22/2021HouseHouse Committee Amendment No. 1 Referred to Rules Committee
  3/23/2021HouseHouse Committee Amendment No. 1 Rules Refers to Prescription Drug Affordability & Accessibility Committee
  3/25/2021HouseAdded Co-Sponsor Rep. Daniel Didech
  3/27/2021HouseRule 19(a) / Re-referred to Rules Committee
  3/27/2021HouseHouse Committee Amendment No. 1 Rule 19(c) / Re-referred to Rules Committee

Back To Top